|(Z)-2-甲氧基-5- (3,4,5-三甲氧基苯烯基)苯酚|CsnPharm

CAS No.: 117048-59-6

Combretastatin A4/康普瑞汀 Catalog No. CSN12500

Synonyms: CRC 87-09;CA-4;Combrestatin A4

Combretastatin A4 is a tubulin polymerization inhibitor with Kd value of 0.4 μM for binding to β-tubulin.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

靶点 β-tubulin

Kd:0.4μM
描述Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
细胞研究

Cell Data

Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources
A10 cells	-	Growth inhibition assay	48 h	Growth inhibition of rat A10 cells after 48 hrs by MTT assay, IC50=0.001 μM	22044164
A-549	-	Growth inhibition assay	-	Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines, ED50=1.20E-06 μM	1875350
ACHN cell	-	Proliferation assay	-	Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay, IC50=0.0016 μM	17286393

更多
动物研究
剂量
Rat: 10 mg/kg, 30 mg/kg^[3] (i.p.) Mice: 4 mg/kg^[4] (i.p.), 150 mg/kg^[5] (i.p.)

给药途径
i.p.
临床研究

动物研究
剂量	Rat: 10 mg/kg, 30 mg/kg^[3] (i.p.) Mice: 4 mg/kg^[4] (i.p.), 150 mg/kg^[5] (i.p.)
给药途径	i.p.

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00395434	Tumors	Phase 1	Completed	-	United Kingdom ... more >> Mount Vernon Hospital Northwood, Middlesex, United Kingdom, HA6 2RN Royal Marsden Hospital Sutton, Surrey, United Kingdom, SM2 5PT Collapse <<
NCT00507429	Anaplastic Thyroid Cancer	Phase 2 Phase 3	Terminated(Low rate of subject... more >> accrual) Collapse <<	-	-
NCT00003698	Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse <<	Phase 1	Completed	-	United Kingdom ... more >> Mount Vernon Hospital Northwood, England, United Kingdom, HA6 2RN Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.1611 mL
- 15.8054 mL
- 31.6107 mL
- 5 mM
- 0.6322 mL
- 3.1611 mL
- 6.3221 mL
- 10 mM
- 0.3161 mL
- 1.5805 mL
- 3.1611 mL

技术信息

CAS号

117048-59-6

储存条件

粉末: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C18H20O5

运输

蓝冰

分子量

316.35

别名

CRC 87-09;CA-4;Combrestatin A4;康普瑞汀

溶解度

DMSO	63.0 mg/mL (199.1 mM)
Water	Insoluble
Ethanol	34.0 mg/mL (107.5 mM) warming

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources

A10 cells	-	Growth inhibition assay	48 h	Growth inhibition of rat A10 cells after 48 hrs by MTT assay, IC50=0.001 μM	22044164
A-549	-	Growth inhibition assay	-	Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines, ED50=1.20E-06 μM	1875350
ACHN cell	-	Proliferation assay	-	Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay, IC50=0.0016 μM	17286393
BNL 1ME A.7R.1 cells	-	Cytotoxicity assay	-	Cytotoxicity against mouse BNL 1ME A.7R.1 cells, IC50=0.0009 μM	25785605
Calu6	-	Proliferation assay	48 h	Antiproliferative activity against human Calu6 after 48 hrs by spectrophotometry, IC50=0.00094 μM	21774499
CEM cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human CEM cells after 72 hrs by MTT assay, IC50=0.001 μM	22676247
DU145 cells	-	Cytotoxicity assay	-	Cytotoxicity against human DU145 cells by SRB assay, GI50=0.00054 μM	24016002
DU145 cells	-	Growth inhibition assay	-	Growth inhibition of human DU145 cells by sulforhodamine B assay, GI50=0.00054 μM	23772309
DU145 cells	-	Cytotoxicity assay	48 h	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay, GI50=0.0008 μM	18303849
DU145 cells	-	Cytotoxicity assay	-	Cytotoxicity against human DU145 cells by SRB assay, GI50=0.001 μM	20496923
DU145 cells	-	Growth inhibition assay	48 h	Growth inhibition of human DU145 cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
H460	-	Cytotoxicity assay	-	Cytotoxicity against human H460 cells by sulforhodamine B test, IC50=0.0012 μM	18783207
H460	-	Proliferation assay	-	Antiproliferative activity against human H460 cells, IC50=0.00124 μM	16722633
HaCaT cells	-	Proliferation assay	-	Antiproliferative activity against human HaCaT cells assessed as cell viability by MTT assay, IC50=0.001 μM	23063401
HCT 116	-	Growth inhibition assay	-	Concentration which produces 50% inhibition of growth of human colon tumor HCT 116, IC50=0.0009 μM	11714613
HCT116 cell	-	Cytotoxicity assay	-	Cytotoxicity against HCT116 cell line, IC50=0.00035 μM	17249649
HCT116 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HCT116 cells assessed as reduction of [3H]thymidine incorporation after 72 hrs by scintillation counting, IC50=0.00074 μM	21955454
HCT116 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay, IC50=0.001 μM	21112130
HCT116 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, IC50=0.001 μM	22676247
HCT15 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HCT15 cells after 72 hrs by MTS assay, IC50=0.001 μM	21112130
HeLa cell	-	Cytotoxicity assay	-	Cytotoxicity against HeLa cell line, IC50=0.0003 μM	17249649
HeLa cells	-	Cytotoxicity assay	-	Cytotoxicity against human HeLa cells by MTT assay, IC50=0.00051 μM	19879758
HeLa cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HeLa cells after 72 hrs by resazurin based fluorescence assay, IC50=0.0009 μM	24669888
HepG2 cells	-	Cytotoxicity assay	-	Cytotoxicity against human HepG2 cells, IC50=0.00014 μM	17127061
HL60 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=0.0001 μM	20731355
HL60 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.001 μM	21663319
HL60 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM	22136312
HL60 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.001 μM	22578111
HL60 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM	23117171
HL60 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HL60 cells after 72 hrs by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test, IC50=0.001 μM	25785605
HL60 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM	20420439
HL60 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=0.001 μM	23445496
Hs578T cells	-	Growth inhibition assay	48 h	Growth inhibition of human Hs578T cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
HT-29	-	Growth inhibition assay	-	Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines, ED50=1.20E-06 μM	1875350
HT-29	-	Growth inhibition assay	-	Growth inhibition of human HT-29 cells by MTT assay, IC50=0.001 μM	25689111
Human SH-SY5Y neuroblastoma cells	-	Function assay	-	Inhibitory concentration against Human SH-SY5Y neuroblastoma cells, IC50=0.0015 μM	15963722
HuTu 80 cells	-	Proliferation assay	72 h	Antiproliferative activity in human HuTu 80 cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00137 μM	22329561
HUVEC	-	Proliferation assay	-	Antiproliferative activity against human HUVEC, IC50=0.0015 μM	16722633
HUVEC cells	-	Growth inhibition assay	48 h	Growth inhibition of HUVEC cells after 48 hrs by MTT assay, IC50=0.001 μM	22044164
K562 cells	-	Cytotoxicity assay	-	Cytotoxicity against human K562 cells, IC50=0.0014 μM	19837594
KB cell	-	Proliferation assay	-	Antiproliferative activity against human KB cell line by methylene blue dye assay, IC50=0.0015 μM	17034147
KBV1 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay, IC50=0.0004 μM	20731355
KB-VIN10 cell	-	Proliferation assay	-	Antiproliferative activity against human KB-VIN10 cell line by methylene blue dye assay, IC50=0.0015 μM	17034147
KB-VIN10 cells	-	Proliferation assay	72 h	Antiproliferative activity against human KB-VIN10 cells over-expressing P-gp 170/MDR1 after 72 hrs by methylene blue assay, IC50=0.0007 μM	21641700
M14	-	Cytotoxicity assay	-	In vitro cytotoxic activity was tested against human melanoma cancer (M14) cell line, GI50=0.0001 μM	12729640
MCF-7	-	Growth inhibition assay	-	Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines, ED50=3.80E-06 μM	1875350
MCF7 cells	-	Proliferation assay	72 h	Antiproliferative activity in human MCF7 cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00111 μM	22329561
MDA-MB-231 cells	-	Growth inhibition assay	48 h	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
MDA-MB-435 cells	-	Growth inhibition assay	48 h	Growth inhibition of human MDA-MB-435 cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
MDA-MB-435 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay, IC50=0.001 μM	22676247
MDA-MB-468 cells	-	Cytotoxicity assay	4 days	Cytotoxicity against human MDA-MB-468 cells assessed as cell viability after 4 days by MTS assay, IC50=0.0011 μM	24210503
melanoma B16 cell	-	Growth inhibition assay	-	Concentration which produces 50% inhibition of growth of murine melanoma B16 cell line, IC50=0.001 μM	11714613
MLM melanoma cell	-	Growth inhibition assay	-	Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines, ED50=1.40E-06 μM	1875350
Molt4/C8 cells	-	Proliferation assay	-	Antiproliferative activity against human Molt4/C8 cells, IC50=0.0016 μM	17034150
Molt4/C8 cells	-	Proliferation assay	3 days	Antiproliferative effect against human Molt4/C8 cells after 3 days, IC50=0.0016 μM	17419607
NCI/ADR (MDR) cells	-	Function assay	-	Cell cycle arrest in NCI/ADR (MDR) cells by accumulation at G2/M phase, IC50=0.0015 μM	16377187
NCI/ADR-RES cells	-	Growth inhibition assay	48 h	Growth inhibition of human NCI/ADR-RES cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
NCI/ADR-RES cells	-	Cytotoxicity assay	-	Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay, IC50=0.0013 μM	23214452
NCI/ADR-RES cells	-	Cytotoxicity assay	96 h	Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy, IC50=0.0013 μM	25025991
NCIH460 cells	-	Cytotoxicity assay	48 h	Cytotoxicity against human NCIH460 cells after 48 hrs by SRB assay, GI50=0.0006 μM	18303849
NCI-H460 cells	-	Cytotoxicity assay	72 h	Cytotoxic activity against human NCI-H460 cells after 72 hrs by sulforhodamine B test, IC50=0.0013 μM	18396857
NCI-H522 cells	-	Growth inhibition assay	48 h	Growth inhibition of human NCI-H522 cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
OVCAR3	-	Growth inhibition assay	48 h	Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
OVCAR8 cells	-	Growth inhibition assay	96 h	Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs, IC50=0.0013 μM	22044164
OVCAR8 cells	-	Cytotoxicity assay	96 h	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy, IC50=0.0013 μM	25025991
OVCAR8 cells	-	Cytotoxicity assay	-	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay, IC50=0.0013 μM	23214452
PC3 cells	-	Growth inhibition assay	48 h	Growth inhibition of human PC3 cells after 48 hrs by SRB assay, GI50=0.001 μM	22982122
RS4:11 cells	-	Proliferation assay	72 h	Antiproliferative activity against human RS4:11 cells after 72 hrs by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test, IC50=0.0008 μM	25785605
SKMEL-5	-	Growth inhibition assay	-	Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines, ED50=3.00E-08 μM	1875350
SK-N-BE	-	Proliferation assay	72 h	Antiproliferative activity in human SK-N-BE cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00058 μM	22329561
SKOV3	-	Cytotoxicity assay	-	Cytotoxicity against human SKOV3 cells by SRB assay, GI50=0.00042 μM	24016002
SK-OV3	-	Cytotoxicity assay	-	In vitro cytotoxic activity tested against human ovarian cancer (SK-OV3) cell line, GI50=0.0001 μM	12729640
SK-OV-3	-	Growth inhibition assay	48 h	Growth inhibition of human SK-OV-3 after 48 hrs by SRB assay, GI50=0.00013 μM	18722127
SKOV3 cells	-	Growth inhibition assay	-	Growth inhibition of human SKOV3 cells by sulforhodamine B assay, GI50=0.00042 μM	23772309
SKOV3 cells	-	Growth inhibition assay	-	Growth inhibition of human SKOV3 cells by MTT assay, IC50=0.001 μM	25689111
SW620 cells	-	Proliferation assay	72 h	Antiproliferative activity in human SW620 cells assessed as cell viability after 72 hrs by MTT assay, IC50=0.00152 μM	22329561
ZR-75-1	-	Cytotoxicity assay	-	Cytotoxicity against ZR-75-1 cell line, IC50=0.00024 μM	17249649

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00395434	Tumors	Phase 1	Completed	-	United Kingdom ... more >> Mount Vernon Hospital Northwood, Middlesex, United Kingdom, HA6 2RN Royal Marsden Hospital Sutton, Surrey, United Kingdom, SM2 5PT Collapse <<
NCT00507429	Anaplastic Thyroid Cancer	Phase 2 Phase 3	Terminated(Low rate of subject... more >> accrual) Collapse <<	-	-
NCT00003698	Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse <<	Phase 1	Completed	-	United Kingdom ... more >> Mount Vernon Hospital Northwood, England, United Kingdom, HA6 2RN Collapse <<
NCT00507429	-	-	Terminated(Low rate of subject... more >> accrual) Collapse <<	-	-
NCT00003768	Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse <<	Phase 1	Completed	-	United States, Ohio ... more >> Ireland Cancer Center Cleveland, Ohio, United States, 44106-5065 Collapse <<
NCT01305213	-	-	Completed	-	-
NCT00653939	Tumors	Phase 2	Completed	-	United States, California ... more >> Southbay Oncology Hematology Campbell, California, United States, 95008 Pacific Coast Hematology and Oncology Medical Group Fountain Valley, California, United States, 92708 UCLA Division of Hematology and Oncology Los Angeles, California, United States, 90095 Bay Area Cancer Research Group, LLC Pleasant Hill, California, United States, 94523 United States, Florida Boca Raton Comprehensive Cancer Center Boca Raton, Florida, United States, 21020 United States, Kentucky Kentuckiana Cancer Institute Louisville, Kentucky, United States, 40202 United States, Massachusetts Lahey Clinic Medical Center Burlington, Massachusetts, United States, 01805 United States, New Jersey The Center for Cancer and Hematologic Disease Cherry Hill, New Jersey, United States, 08003 United States, New Mexico San Juan Oncology Associates Farmington, New Mexico, United States, 87401 United States, Ohio Gabrail Cancer Center Canton, Ohio, United States, 44718 The Mark H. Zangmeister Center Columbus, Ohio, United States, 43219 Signal Point Clinical Research Middletown, Ohio, United States, 45042 United States, Virginia Blueridge Cancer Care Salem, Virginia, United States, 24153 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98405 United States, West Virginia Mary Babb Randolph Cancer Center-Clinical Trials Unit Morgantown, West Virginia, United States, 26506 Collapse <<
NCT01305213	Recurrent Fallopian Tube Carci... more >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Collapse <<	Phase 2	Completed	-	-
NCT01052363	Central Nervous System Tumors	Phase 1	Withdrawn(No funding)	-	United States, West Virginia ... more >> MBRCC, West Virginia University Morgantown, West Virginia, United States, 26506 Collapse <<
NCT01023295	Polypoidal Choroidal Vasculopa... more >>thy Collapse <<	Phase 2	Completed	-	United States, California ... more >> OXiGENE Investigational Site Los Angeles, California, United States Hong Kong OXiGENE Investigational Site Hong Kong, Hong Kong Korea, Republic of OXiGENE Investigational Site Seoul, Korea, Republic of Singapore OXiGENE Investigational Site Singapore, Singapore Taiwan OXiGENE Investigational Site Changhua, Taiwan Collapse <<
NCT00077103	Head and Neck Cancer	Phase 1 Phase 2	Terminated(slow accrual)	-	United States, Michigan ... more >> Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 United States, Pennsylvania Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 Collapse <<
NCT00653939	-	-	Completed	-	-
NCT02132468	Neuroendocrine Tumors	Phase 2	Completed	-	United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Kentucky Markey Cancer Center, Clinical Research Office Lexington, Kentucky, United States, 40356 United States, New York Montefiore Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Wisconsin Froedtert Hospital, Medicial College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Collapse <<
NCT02132468	-	-	Completed	-	-
NCT03014297	Neuroendocrine Tumors ... more >> Everolimus Collapse <<	Phase 1	Active, not recruiting	June 30, 2019	United States, Kentucky ... more >> University of Kentucky Markey Cancer Center Lexington, Kentucky, United States, 40502 Collapse <<
NCT00060242	Head and Neck Cancer	Phase 2	Completed	-	United States, Michigan ... more >> Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 United States, Pennsylvania Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 Collapse <<
NCT02055690	Ovarian Neoplasms ... more >> Neoplasms, Ovarian Ovarian Cancer Collapse <<	Phase 1 Phase 2	Terminated(Safety)	-	United Kingdom ... more >> Royal United Hospital Bath NHS Trust Bath, United Kingdom, BA1 3NG City Hospital Birmingham, United Kingdom, B18 7GH University Hospitals Bristol NHS Foundation Trust Bristol, United Kingdom, BS1 3NU University Collage London Hospitals NHS Foundation Trust London, United Kingdom, NW1 2PG The Royal Marsden NHS Foundation Trust London, United Kingdom, SM2 5PT The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Clatterbridge Centre for Oncology NHS Foundation Trust Merseyside, United Kingdom, CH63 4JY Mount Vernon Cancer Centre (East and North Herts NHS Trust) Middlesex, United Kingdom, HA6 2RN Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust) Newcastle-upon-Tyne And Wear, United Kingdom, NE7 7DN Oxford Radcliffe Hospitals NHS Trust Oxford, United Kingdom, OX3 9DU Collapse <<
NCT00113438	Cancer Tumor	Phase 2	Completed	-	United States, Utah ... more >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Collapse <<
NCT01701349	Anaplastic Thyroid Cancer	Phase 3	Withdrawn(Expected inability t... more >>o recruit study participants in a reasonable amount of time.) Collapse <<	December 2017	-
NCT01570790	Combretastatin A4 Phosphate ... more >> Age-related Macular Degeneration AMD CNV Choroidal Neovascularization Collapse <<	Phase 1 Phase 2	Completed	-	United States, Maryland ... more >> Wilmer Eye Institute Baltimore, Maryland, United States, 21287 Collapse <<
NCT02279602	Neuroendocrine Tumors	Phase 2	Completed	-	United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Kentucky Markey Cancer Center, Clinical Research Office Lexington, Kentucky, United States, 40356 United States, New York Montefiore Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Wisconsin Froedtert Hospital, Medicial College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Collapse <<
NCT01423149	Choroidal Neovascularization ... more >> Myopia, Degenerative Collapse <<	Phase 2	Completed	-	-
NCT02641639	Platinum Resistant Ovarian Can... more >>cer Collapse <<	Phase 2 Phase 3	Terminated(Interim analysis fa... more >>iled to show efficacy benefit) Collapse <<	-	-

Combretastatin A4/康普瑞汀 Catalog No. CSN12500

靶点选择性

请登录您的专属账户

确认信息